Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:4/27/2017)... Minneapolis, Minnesota (PRWEB) , ... April 27, 2017 ... ... Smith and her husband Dan Gasby the 2017 Public Leadership in Neurology Award ... Bob Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... announced an exhibitor sponsorship at MobileIron Live! 2017 in Santa Clara, ... for an immersive, educational approach to helping organizations maximize the benefits of mobility ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched in ... market has seen before. Swissx uses proprietary strains of hemp plants grown in the ... extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn more ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to announce that ... at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego Convention ... will lend their expertise to the Premier Global Hot Topics session, speaking on genital ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... and clinical outcomes, today released the podcast, “Make Plans for MACRA,” ... value-based payment into the physician's office and how physicians and other clinicians are ...
Breaking Medicine News(10 mins):
(Date:4/25/2017)... 2017 Endo International plc (NASDAQ: ENDP ) ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 6086379. Please dial in 10 minutes prior to ... replay of the call will be available from May 9, 2017 ...
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... and Gynecology markets with innovative and proprietary products, ... Company as Senior Vice President, Marketing & Business ... will report directly to Darin Hammers , ... delighted that Ash has joined the Cogentix team," ...
Breaking Medicine Technology: